BioNTech Puts Up $200M to Partner With OncoC4 in Cancer Immunotherapy
BioNTech’s messenger RNA technology led to a successful Covid-19 vaccine that provides it with plenty of cash for pipeline expansion. The company is deploying some of that capital in a…